Medtronic continuous glucose management system receives CE Mark

Medtronic's new innovative new Sentrino continuous glucose management (CGM) system has been granted European regulatory approval.

The device, which is the first minimally invasive CGM system specifically designed for use in hospital critical care units, has received CE Mark accreditation and is now set to play a key role in optimising glucose management practices.

Sentrino provides real-time trend data to serves as an early warning system and help doctors appropriately intervene to prevent glycaemic excursions, while it has also been designed to integrate seamlessly into clinical workflows.

Other benefits include its minimally-invasive subcutaneous sensor, novel drug interference rejection technology and easy configuration.

Greg Meehan, vice-president and general manager of the CGM business at Medtronic, said: "Medtronic has a decade of CGM expertise and we coupled it with extensive clinical research to develop the Sentrino CGM System for critically ill patients."

Last month, the company announced clinical data for its Endurant AAA stent graft system, which demonstrated the benefits it can provide in abdominal aortic aneurysm repair procedures.